Article
Cardiac & Cardiovascular Systems
Raphael Porcher, Isabelle Desguerre, Helge Amthor, Brigitte Chabrol, Frederique Audic, Francois Rivier, Arnaud Isapof, Vincent Tiffreau, Emmanuelle Campana-Salort, France Leturcq, Sylvie Tuffery-Giraud, Rabah Ben Yaou, Djillali Annane, Pascal Amedro, Christine Barnerias, Henri Marc Becane, Anthony Behin, Damien Bonnet, Guillaume Bassez, Mireille Cossee, Gregoire de La Villeon, Claire Delcourte, Abdallah Fayssoil, Bertand Fontaine, Francois Godart, Sophie Guillaumont, Emmanuelle Jaillette, Pascal Laforet, Sarah Leonard-Louis, Frederic Lofaso, Michele Mayer, Raul Juntas Morales, Christophe Meune, David Orlikowski, Caroline Ovaert, Helene Prigent, Malika Saadi, Maximilien Sochala, Celine Tard, Guy Vaksmann, Ulrike Walther-Louvier, Bruno Eymard, Tanya Stojkovic, Philippe Ravaud, Denis Duboc, Karim Wahbi
Summary: Prophylactic ACEi treatment in patients with Duchenne muscular dystrophy is associated with significantly higher overall survival and lower rates of hospitalization for heart failure.
EUROPEAN HEART JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Zsofia Onodi, Petra Lujza Szabo, Daniel Kucsera, Peter Pokreisz, Christopher Dostal, Karlheinz Hilber, Gavin Y. Oudit, Bruno K. Podesser, Peter Ferdinandy, Zoltan V. Varga, Attila Kiss
Summary: Duchenne muscular dystrophy (DMD) is a muscle wasting disease characterized by difficulty moving and premature death, mainly due to heart failure. Inflammation is thought to play a role in the disease progression, but the specific mechanisms are not well understood.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Steven D. Brooks, Rachel L. Smith, Aline S. Moreira, Hans C. Ackerman
Summary: Lisinopril increases ACE2 expression in tissues relevant to COVID-19, while adding losartan prevents the lisinopril-induced increase. A sex difference was observed with higher ACE2 levels in the kidneys of male mice.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Antonis A. Manolis, Theodora A. Manolis, Antonis S. Manolis
Summary: In patients with heart failure, the activation of neuroendocrine systems like the sympathetic nervous system, renin-angiotensin-aldosterone system, and arginine vasopressin system leads to tachycardia and increased systemic vascular resistance. Sustained neurohormonal activation plays a crucial role in the progression and worsening of heart failure. Biomarkers such as natriuretic peptides, catecholamine levels, and neprilysin can be used to understand heart failure drug mechanisms and identify patients who may benefit from specific therapies. Neurohumoral antagonists, including beta blockers, ACE inhibitors/angiotensin receptor blockers, and vaptans, target these neurohormonal systems. The introduction of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan has enhanced the actions of natriuretic peptides by combining RAAS inhibition and neprilysin blocking.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Persoulla A. Nicolaou
Summary: Sex-related differences in clinical manifestations, risk factors, and treatment drug use in patients with heart failure are significant, particularly in the regulation of the renin-angiotensin-aldosterone system (RAAS). While current evidence suggests potential differences in the efficacy of RAAS drugs between men and women, further research is needed to determine the optimal treatment strategies for both genders.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Xu Zhu, Jing Xue, Zheng Liu, Wenjie Dai, Jingsha Xiang, Hui Xu, Qiaoling Zhou, Quan Zhou, Xinran Wei, Wenhang Chen
Summary: The use of ACEI/ARB treatment in patients with AKI may reduce all-cause mortality but increases the risk of AKD.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ilaria Caputo, Brasilina Caroccia, Ilaria Frasson, Elena Poggio, Stefania Zamberlan, Margherita Morpurgo, Teresa M. Seccia, Tito Cali, Marisa Brini, Sara N. Richter, Gian Paolo Rossi
Summary: Blockers of the renin-angiotensin system (RAS) can increase the expression of ACE2, the cellular receptor of SARS-CoV-2, and thus increase the risk of COVID-19. This study found that angiotensin II (Ang II) significantly increased the levels of ACE2 expression by acting on the angiotensin type 1 receptor, resulting in enhanced viral entry into cells. However, the blockade of ACE-1-mediated Ang II formation and ACE2-mediated Ang II conversion did not have any effect. Therefore, increased production of Ang II in patients with an activated RAS may lead to a greater spread of COVID-19 infection in lung cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Jiuyang Xu, Yaqun Teng, Lianhan Shang, Xiaoying Gu, Guohui Fan, Yijun Chen, Ran Tian, Shuyang Zhang, Bin Cao
Summary: The study found no association between prior use of ACEI/ARB and the risk of COVID-19 infection, and using ACEI/ARB did not change the severity of the disease among patients. This suggests that the current medical guidelines and position statements supporting the continuation of ACEI/ARB use are evidence-based and appropriate.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, Research & Experimental
Cedric Happi Mbakam, Joel Rousseau, Yaoyao Lu, Anne Bigot, Kamel Mamchaoui, Vincent Mouly, Jacques P. Tremblay
Summary: In this study, researchers used CRISPR-Cas9 prime editing technology to correct a mutation in the DMD gene, resulting in improved editing efficiency and restoration of dystrophin protein expression. Optimization of the reverse transcription template sequence led to a significant increase in the editing percentage of the target nucleotide.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2022)
Article
Medicine, General & Internal
Seok Hui Kang, Bo Yeon Kim, Eun Jung Son, Gui Ok Kim, Jun Young Do
Summary: This study aimed to evaluate patient survival with the use of renin-angiotensin system blockers (RASBs) in maintenance hemodialysis (HD) patients, and found that the use of RASBs was associated with higher patient survival rates.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Geriatrics & Gerontology
Lorna Caulfield, Philip Heslop, Katherine E. Walesby, Deepa Sumukadas, Avan A. Sayer, Miles D. Witham
Summary: The current evidence does not support the use of ACE inhibitors or angiotensin receptor blockers as a single intervention to improve physical performance in older people, based on a systematic review and meta-analysis of randomized controlled trials.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2021)
Article
Pharmacology & Pharmacy
Kung-Ming Laio, Chuan-Wei Shen, Yun-Hui Huang, Chun-Hui Lu, Hsuan-Lin Lai, Chung-Yu Chen
Summary: The prescription pattern and effectiveness of antihypertensive drugs in surgical patients with aortic dissection were investigated. The study found that no specific type of antihypertensive drug was associated with a better outcome in patients with type A aortic dissection, while the use of beta-blockers and calcium channel blockers (CCBs) was related to a significantly lower risk of the composite outcome in patients with type B aortic dissection.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Ruxin Wang, Haowen Ye, Yongting Zhao, Jinjing Wei, Ying Wang, Xiaofang Zhang, Lihong Wang
Summary: This meta-analysis found that sacubitril/valsartan has a positive effect on glycemic control and the prevention of new-onset diabetes mellitus, especially in patients with heart failure.
Article
Pharmacology & Pharmacy
Taikang Yao, Zhenchao Wu, Zilu Wang, Liting Chen, Beibei Liu, Ming Lu, Ning Shen
Summary: Observational studies and meta-analyses have shown a positive correlation between the use of angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer. The study used Mendelian randomization to verify the associations between ACE inhibition, ACEI-induced cough, and the risk of lung cancer. The results indicate a significant relationship between ACE inhibition and the development of lung cancer, as well as a higher risk of lung cancer for Europeans with ACEI-induced cough.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Genetics & Heredity
Carina M. Mathey, Carlo Maj, Annika B. Scheer, Julia Fazaal, Bettina Wedi, Dorothea Wieczorek, Philipp M. Amann, Harald Loffler, Lukas Koch, Clemens Schoffl, Heinrich Dickel, Nomun Ganjuur, Thorsten Hornung, Susann Forkel, Jens Greve, Gerda Wurpts, Par Hallberg, Anette Bygum, Christian Von Buchwald, Malgorzata Karawajczyk, Michael Steffens, Julia Stingl, Per Hoffmann, Stefanie Heilmann-Heimbach, Elisabeth Mangold, Kerstin U. Ludwig, Eva R. Rasmussen, Mia Wadelius, Bernhardt Sachs, Markus M. Nothen, Andreas J. Forstner
Summary: This study investigated the possible association between ACEi/ARB-induced angioedema and HAE genes through molecular genetic screening. The results suggest that HAE-associated mutations are, at best, a rare cause of ACEi/ARB-induced angioedema, and there was no significant association found between ACEi/ARB-induced angioedema and other variants in the investigated genes.
FRONTIERS IN GENETICS
(2022)
Review
Cardiac & Cardiovascular Systems
Peiyue Zhang, Cuiyuan Huang, Haiyin Liu, Mengting Zhang, Li Liu, Yuhong Zhai, Jing Zhang, Jian Yang, Jun Yang
Summary: NFAT is a widely expressed transcriptional activator that is involved in regulating the immune system, heart and brain development, and mediating pathological processes such as cardiac hypertrophy. Oxidative stress, characterized by excessive production of reactive oxygen species, mitochondrial dysfunction, calcium overload, and subsequent lipid peroxidation, inflammation, and apoptosis, is associated with various pathological processes. Calcium overload activates NFAT through the calcium-calcineurin pathway, which is the main regulatory mode of NFAT factors. This review focuses on the effects of NFAT transcription factors on reactive oxygen species production, calcium overload, mitochondrial dysfunction, redox reactions, lipid peroxidation, inflammation, and apoptosis in response to oxidative stress. The aim is to provide a reference for understanding the functions and characteristics of NFAT in different stages of oxidative stress and related potential targets.
JOURNAL OF CARDIOLOGY
(2024)